EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license)

Neovascular (Wet) Age-Related Macular Degeneration

200K US cases/yr

Disease Overview

Wet (neovascular) age-related macular degeneration is driven by choroidal neovascularization — abnormal, leaky blood vessel growth under the macula stimulated by VEGF — causing rapid central vision loss in older adults. Although wet AMD represents only ~10% of all AMD cases, it accounts for ~90% of legal blindness from the disease, making timely VEGF blockade essential.

Competitive Landscape

When NeXstar/Gilead licensed NX-1838 to EyeTech in March 2000, standard-of-care for wet AMD was thermal laser photocoagulation and Novartis/QLT's verteporfin (Visudyne) photodynamic therapy — both vision-preserving at best, not vision-restoring. NX-1838, a pegylated 28-nucleotide RNA aptamer selectively binding VEGF165, became pegaptanib (Macugen) and was approved by FDA in December 2004 as the first anti-VEGF therapy and first aptamer ever approved. Macugen's window of dominance was brief: ranibizumab (Lucentis, Genentech/Novartis), a Fab fragment binding all VEGF-A isoforms, was approved June 2006 and demonstrated vision improvement in roughly 30-40% of patients versus Macugen's vision-stabilization profile — Macugen showed ~6% improvement at 1 year with a maximal response rate near 70% versus Lucentis's ~95%. Off-label intravitreal bevacizumab (Avastin) at ~$40-75/injection further eroded Macugen's $1,000/injection economics, and aflibercept (Eylea, Regeneron, 2011) and now faricimab (Vabysmo, Roche, 2022) and biosimilar/long-acting players have rendered pegaptanib essentially obsolete as monotherapy. The deal mattered historically: $7M upfront and up to $25M in milestones to Gilead from EyeTech created the first commercially-validated anti-VEGF franchise in ophthalmology and seeded a market category that today exceeds $10B globally.